Under the auspices of the Lebanese Association for Oncology, IPS Genomix has organized a symposium on the concept of Personalized Medicine in Oncology, hosted by Professor Fadlo Khuri, head of hematology – oncology section at Emory University and vice president of Winship Cancer Institute-USA.
First, the IPS (Integrated Pharma Solutions) Group CEO, Ahmed Yacout, talked about the interest given by the company to Personalized Medicine in Oncology.
The president of the Lebanese Society of Medical Oncology and chairman of the hematology-oncology department at Hotel Dieu de France University hospital, Professor George Chahine, has inaugurated the symposium.
A session has been dedicated to discussing and answering the questions of the participants, and was shared by the head of the hematology-oncology division at AUBMC, Professor Ali Shamseddine.
The participants followed with great interest the presentation of Professor Khuri that comprised the development stages of Personalized Medicine in Oncology, since “the existing scientific revolution in the fields of medicine and genetic researches has engendered a positive development in the quality of health care provided to cancer patients.
The idea of personalized medicine is not new. However, nowadays, with the technique of detailed genetic tests, a more precise and efficient personalized treatment is possible to eradicate the cancerous tumor, with less side effects on the patient.”
He added: “We are at a time when the cost of treating cancer is high, whether it is a chemical treatment or a targeted therapy. Now, and due to genetic tests, we are capable of knowing more details about the tumor, about each patient and the specificity of his case. This means that we are capable of obtaining better results, at a lower cost.”